Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Key Little Things That Advantage Old People - 2Vagus nerve stimulation shows promise as a way to counter Alzheimer’s disease- and age-related memory loss
- 3These four astronauts could soon travel farther from Earth than anyone has gone before
- 4Black Friday streaming deals 2025: Grab the Disney+ Hulu bundle for only $5 and save over 60%
- 5Woman leaves bachelorette trip after trusting her gut about sketchy men partying it up with friends
- Enormous Credit And All that You Really want To Be aware
- The Best Web-based Courses for Ability Advancement
- Where is Santa right now? NORAD tracks his 2025 Christmas Eve flight.
- US bishops officially ban gender-affirming care at Catholic hospitals
- Consume Fat Quick: 10 Demonstrated Activities for Ideal Outcomes
- Gov’t approves millions for border cities in North under Hezbollah fire
- Find the Effect of Web-based Entertainment on Society: Exploring the Computerized Scene
- Here's how 'Bridgerton' fans can watch the first episode of Season 4 before its Netflix release later this month
- European nations criticise Israel’s death penalty plans
